Energy balance
Metformin activates AMPK indirectly by inhibiting mitochondrial Complex I, leading to increased AMP/ADP ratios, but its primary therapeutic benefit in lowering hepatic glucose production is mediated by AMPK-independent mechanisms involving adenylate cyclase inhibition.
Metformin is a first-line treatment for type 2 diabetes. While it does activate energy-sensing pathways (AMPK), its ability to lower blood sugar in the liver also works through other mechanisms involving cellular energy levels. This complexity does not diminish its status as a standard, effective therapy.
it now appears likely that the effects of metformin to inhibit hepatic glucose production are not mediated by AMPK but by other mechanisms such as the inhibition of adenylate cyclase and/or fructose-1,6-bisphosphatase by AMP.
Why this rating
Based on a comprehensive review of multiple animal knockout studies and human retrospective analyses, though direct human mechanistic trials for the specific AMPK-independent pathway are less emphasized than the general association.
Source
AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
D. Grahame Hardie · Diabetes · 2013
DOI 10.2337/db13-0368
More from this paper
- Salicylate (the active metabolite of aspirin and salsalate) activates AMPK directly by binding to the beta-1 subunit, independent of AMP/ADP levels, and improves metabolic parameters in subjects with insulin resistance.Moderate
- Metformin use is associated with a significantly lower incidence of cancer (approx. 30% risk reduction) in type 2 diabetic patients, likely mediated by AMPK activation which suppresses tumor growth.Moderate
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →